

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark Edward Bunnage, et al. : Examiner:
To Be Assigned : To Be Assigned
APPLICATION NO.: To Be Assigned : Group Art Unit: To Be Assigned
FILING DATE: Herewith :
TITLE: Pyrazolopyrimidinones Which Inhibit Type 5 Cyclic :
Guanosine 3',5'-Monophosphate Phosphodiesterase
(cGMP-PDE5) For The Treatment of Sexual
Dysfunction :
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MARCH 23, 2004


James J. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903

EXPRESS MAIL NO. EV 271824876 US

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. PC9430BJTJ	SERIAL NO. To Be Assigned
	APPLICANT Mark E. Bunnage, et al.	
	FILING DATE Herewith	GROUP To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5	4	2	6	1	0	7	20 June 95	Bell et al.	514	234.2	
		5	3	4	6	9	0	1	13 Sept 94	Bell et al.	514	258	
		5	7	1	9	2	8	3	17 Feb 98	Bell et al.	544	262	
		5	7	3	4	0	5	3	31 Mar 98	Terrett	544	277	
		4	6	6	6	9	0	8	19 May 87	Hamilton	514	229	
		4	6	6	3	3	2	6	5 May 87	Hamilton	514	258	
		5	2	7	2	1	4	7	21 Dec 93	Bell et al	514	234.2	
		3	9	9	2	4	4	1	16 Nov 76	Helland	260	518	
		4	6	6	8	2	8	0	26 May 87	Gehring et al	71	92	
		5	9	5	5	6	1	1	21 Sept 99	Dunn et al	544	262	
		4	8	7	1	8	4	3	3 Oct 89	Roger et al	540	575	
		5	2	9	4	6	1	2	15 March 94	Bacon et al	514	234.2	
		5	7	3	6	5	4	8	7 April 98	Baco et al	514	258	
		5	2	5	0	5	3	4	5 Oct 93	Bell et al	514	258	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	9	5	4	3	3	3	28 Oct 99	International	C07D	487/04		
	WO	9	6	1	6	6	5	7	6 June 96	International	A61K	31/505		
	WO	9	4	0	0	4	5	3	6 Jan 94	International	C07D	473/30		
	WO	9	4	0	5	6	6	1	17 Mar 94	International	C07D	471/04		
	WO	9	3	1	2	0	9	5	24 June 93	International	C07D	239/91		
	WO	9	3	0	7	1	4	9	15 April 93	International	C07D	487/04		
	WO	9	3	0	6	1	0	4	1 April 93	International	C07D	487/04		
	WO	9	6	2	8	4	2	9	19 Sept 96	International	C07D	239/70		
	WO	9	6	2	8	4	4	8	19 Sept 96	International	C07D	487/04		
	EP	0	3	4	9	2	3	9	16 Mar 94	EPO	C07D	487/04		
	EP	0	6	3	6	6	2	6	1 Feb 95	EPO	C07D	487/04		
	WO	9	4	2	8	9	0	2	22 Dec 94	International	A61K	31/505		
	WO	9	6	1	6	6	4	4	6 June 1996	International	A61K	31/00		
	EP	0	2	0	1	1	8	8	17 Dec 86	EPO	C07D	487/04		

EXPRESS MAIL NO. EV271824876US

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>						ATTY. DOCKET NO. PC9430BJTJ				SERIAL NO. To Be Assigned			
						APPLICANT Mark E. Bunnage, et al.							
						FILING DATE Herewith				GROUP To Be Assigned			

EP	0	3	5	2	9	6	0	31 Jan 1990	EPO	C07D	31/52		
EP	0	4	4	2	2	0	4	21 Aug 1991	EPO	C07D	487/04		
EP	0	3	7	1	7	3	1	6 June 1990	EPO	C07D	239/91		
EP	0	5	7	9	4	9	6	19 Jan 1994	EPO	C07D	401/04		
EP	0	4	6	3	7	5	6	2 Jan 92	EPO	C07D	487/04		
EP	0	5	2	6	0	0	4	7 Feb 1992	EPO	C07D	487/04		
WO	9	9	6	4	0	0	4	16 Dec 1999	International	A61K	31/505		
WO	9	8	4	9	1	6	6	5 Nov 1998	International	C07D	487/04		
WO	9	9	6	4	0	0	4	16 Dec 99	International	A61K	31/505		
WO	9	3	1	5	0	6	2	5 Aug 93	International	C07D	241/04		

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>													
		DuMaitre et al., J. Med. Chem. 39(8), 1996, 1635-1644											
		Bowman et al., Br. J. Pharmacol., 1984, 81(4), pg 665											
		Am. J. Physiol, 1993, 264(2), p H419											
		Rajfer et al., New Eng. J. Med., 1992, 326(2), pg 90											
		J. Urol., 1993, 149(4), pg 285A											
		Murray, Drug News & Perspective, 1993, 6(23), pg 150											
		Sohn et al., Int. J. Imp. Res., 1992, 4(S2), pg 11											
		J. Urol., 1992, 147(S4), pg 454A											
		Harriet W. Hamilton, et al., J. Med. Chem. 1987, 30, pgs 91-96											
		Czarniecki et al in Annual Reports in Medicinal Chemistry, 31, 61-70											
		Henze et al., J. Am. Chem. Soc., Feb, 1939, pgs 433-435											
		Terfort et al., J. Chem.. Soc, Perkin Trans. 1, 1996, pgs 1467-1479											

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.